Free Trial

Sorrento Therapeutics (SRNE) Competitors

Sorrento Therapeutics logo
$0.0080 +0.00 (+14.29%)
As of 10/20/2025 03:53 PM Eastern

SRNE vs. LSB, PHXM, IMCC, KALA, ADXN, ERNA, XBIO, BFRI, SNPX, and INAB

Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include LakeShore Biopharma (LSB), PHAXIAM Therapeutics (PHXM), IM Cannabis (IMCC), KALA BIO (KALA), Addex Therapeutics (ADXN), Ernexa Therapeutics (ERNA), Xenetic Biosciences (XBIO), Biofrontera (BFRI), Synaptogenix (SNPX), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry.

Sorrento Therapeutics vs. Its Competitors

LakeShore Biopharma (NASDAQ:LSB) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

LakeShore Biopharma has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

LakeShore Biopharma has higher revenue and earnings than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LakeShore Biopharma$85.67M0.13-$13.93MN/AN/A
Sorrento Therapeutics$60.32M0.07-$572.84MN/AN/A

In the previous week, LakeShore Biopharma had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for LakeShore Biopharma and 0 mentions for Sorrento Therapeutics. LakeShore Biopharma's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
LakeShore Biopharma Neutral
Sorrento Therapeutics Neutral

52.6% of LakeShore Biopharma shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
LakeShore BiopharmaN/A N/A N/A
Sorrento Therapeutics N/A N/A N/A

Summary

LakeShore Biopharma beats Sorrento Therapeutics on 5 of the 7 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

MetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.86M$347.81M$6.13B$10.54B
Dividend YieldN/AN/A5.72%4.85%
P/E RatioN/AN/A29.4827.34
Price / Sales0.07502.23551.26220.24
Price / CashN/A22.4425.8230.35
Price / BookN/A3.7712.366.69
Net Income-$572.84M-$127.22M$3.32B$276.46M
7 Day PerformanceN/A-1.99%1.83%-0.08%
1 Month PerformanceN/A7.82%8.83%3.93%
1 Year PerformanceN/A4.80%62.18%33.89%

Sorrento Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRNE
Sorrento Therapeutics
1.0095 of 5 stars
$0.01
+14.3%
N/A+158.1%$3.86M$60.32M0.00800Gap Down
LSB
LakeShore Biopharma
N/A$0.53
-33.0%
N/A-83.2%$11.01M$85.67M0.00773High Trading Volume
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
IMCC
IM Cannabis
0.0938 of 5 stars
$1.95
+1.0%
N/A-3.4%$10.13M$39.44M-3.61340Negative News
KALA
KALA BIO
4.0984 of 5 stars
$1.49
+4.2%
$20.38
+1,267.4%
-81.7%$10.04M$3.89M-0.2230Short Interest ↑
ADXN
Addex Therapeutics
1.0762 of 5 stars
$8.52
-9.7%
N/A-13.9%$10M$460K-25.0630Gap Down
ERNA
Ernexa Therapeutics
0.2935 of 5 stars
$1.25
-3.5%
N/A-91.8%$9.93M$580K-0.1510Short Interest ↑
Gap Up
XBIO
Xenetic Biosciences
1.432 of 5 stars
$5.37
-15.2%
N/A+7.3%$9.76M$2.50M-2.694Short Interest ↓
Gap Up
BFRI
Biofrontera
1.7757 of 5 stars
$0.94
-1.9%
$2.75
+191.9%
+17.8%$9.73M$37.32M-0.4270
SNPX
Synaptogenix
N/A$6.89
-2.8%
N/A+123.3%$9.58MN/A-0.684Gap Down
High Trading Volume
INAB
IN8bio
3.53 of 5 stars
$2.17
+3.3%
$92.00
+4,139.6%
-73.6%$9.53MN/A-0.2420

Related Companies and Tools


This page (NASDAQ:SRNE) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners